This year, both Eli Lilly and Novo Nordisk have filed several NAD challenges against compounding pharmacies, telehealth companies and medspas marketing compounded versions of semaglutide and tirzepatide
5, in Nature Medicine seems to back up the FDAs preliminary findings.[1] Rong Xu, PhD, a professor of biomedical informatics and director of the Center for AI in Drug Discovery at Case Western Reserve University, and colleagues examined data from more than 240,000 overweight or obese patients prescribed either semaglutide or non-GLP-1 receptor agonist anti-obesity medications
Importantly, this specific sensory adverse reaction is not currently listed on the official drug labels (prescribing information) for semaglutide or tirzepatide
GLP-1 [receptor agonists] engage multiple neurobiological pathways that are implicated in MS., Shirani said
Additionally, while some data extend to 120 weeks, real-world evidence on treatment adherence, long-term safety, and durability beyond two years is still lacking
In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring
